Subclinical Atrial Fibrillation and the Risk of Stroke: An Interview (20 Jan 2012)
Daniela J Lamas, MD and Gervasio Antonio Lamas, MDA NEJM editorial fellow interviews a NEJM editorialist about subclinical AF and the risk of stroke.
You are browsing articles on the topic of Anticoagulation
ASSERT Sheds Light on the Role of Subclinical AF in Stroke (11 Jan 2012)
A new study published in the New England Journal of Medicine sheds some much-needed light on the precise role of subclinical atrial fibrillation (AF) in the prognosis and development of ischemic stroke. ASSERT (Asymptomatic Atrial Fibrillation and Stroke Evaluation in Pacemaker Patients and the Atrial Fibrillation Reduction Atrial Pacing Trial) followed 2580 patients with a newly implanted pacemaker or ICD…
This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.
Excess Risk for Cardiac Events Associated with Dabigatran (9 Jan 2012)
A new meta-analysis finds that dabigatran is associated with a higher risk of myocardial infarction and acute coronary syndromes. An editorial raises questions about the enthusiasm to embrace new drugs.
J&J Applies for ACS Indication for Rivaroxaban (Xarelto) (29 Dec 2011)
Based on the promising results of the recently published ATLAS ACS 2 TIMI 51 trial, Johnson & Johnson has submitted a supplemental new drug application to the FDA for the approval of rivaroxaban (Xarelto) to reduce the risk of thrombotic cardiovascular events in ACS patients. Following a succession of failed trials, ATLAS was the first trial…
This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.
No Mortality Benefit of Low-Molecular-Weight Heparin in Acutely Ill Patients (28 Dec 2011)
Although venous thromboembolism (VTE) is a serious problem for acutely ill patients in the hospital, a new study published in the New England Journal of Medicine failed to find any improvement in mortality associated with thromboprophylaxis. Ajay Kakkar and the LIFENOX investigators randomized 8307 acutely ill patients to receive enoxaparin or placebo for 10 days. All patients wore…
This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.
FDA Undertakes Safety Review of Dabigatran (Pradaxa) (7 Dec 2011)
The FDA announced today that it is initiating a safety review of dabigatran (Pradaxa, Boehringer Ingelheim). The review was prompted by reports of serious bleeding events in people taking the drug. Bleeding complications, the FDA acknowledges, are a “a well-recognized complication of all anticoagulant therapies.” The agency says it is “working to determine whether the reports of…
This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.
Meta-Analysis Finds Benefits for Self-Monitoring in Some Warfarin Patients (1 Dec 2011)
Despite the advent of newer anticoagulants that don’t require monitoring, millions of people will continue to take warfarin for many years to come. Now a new meta-analysis published in the Lancet suggests that some of these patients may benefit from self-monitoring. Carl Heneghan and colleagues analyzed data from 11 trials with 6417 patients on oral anticoagulation and 12,800…
This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.
ADOPT Fails to Support Extended Oral Apixaban in High-Risk Post-Discharge Patients (13 Nov 2011)
Although medically ill patients remain at risk for VTE after hospital discharge, a strategy of extended oral anticoagulation with apixaban did not prove to be successful in the ADOPT (Apixaban Dosing to Optimize Protection from Thrombosis) trial, which was presented by Samuel Z. Goldhaber at the American Heart Association and published simultaneously in the New England…
This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.
ATLAS ACS 2-TIMI 51: Rivaroxaban Benefits Low-Risk ACS Patients (13 Nov 2011)
Results of the highly anticipated ATLAS-ACS 2–TIMI 51 trial demonstrate that ACS patients receiving standard therapy, including dual antiplatelet therapy, may benefit from the addition of the factor Xa inhibitor rivaroxaban, although at the cost of some additional bleeding complications. The Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome trial was…
This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.
TRACER: Novel Antiplatelet Vorapaxar Runs Into Trouble in ACS (13 Nov 2011)
The novel antiplatelet vorapaxar, which blocks the thrombin receptor to inhibit platelet activation, ran into trouble in the TRACER (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome) trial, which was stopped prematurely earlier this year due to safety concerns. TRACER was presented at the AHA by Ken Mahaffey and published simultaneously in the New England Journal…
This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.
